GT Biopharma, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
GT Biopharma closed a securities purchase on September 18, 2026, issuing 8,611.1111 shares of Series M 10% Convertible Preferred Stock (with stated value of $8.61M) for $7.75M cash to Five Narrow Lane, L.P., Bristol Investment Fund, Ltd., and newly added investor Nicholas R. Nikolov. The amendment also grants purchasers Greenshoe rights to purchase up to $34.68M additional stated value of preferred stock for $31.21M. Series M share count increased from 41,778 to 43,287 authorized shares.
Why this rating
Raises ~90% of company's $8.6M market value in fresh capital with follow-on optionality; highly dilutive but critical for microcap survival and growth.
Price action (we called it positive)
before filing · preread $7.18 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.